| Literature DB >> 32467668 |
Zhuo-Zheng Liang1, Cheng Guo2, Man-Man Zou1, Ping Meng1, Tian-Tuo Zhang1.
Abstract
Circular RNAs, as hopeful diagnosis markers and therapeutic molecules, have been studied, probed and applied into several diseases, such as cardiovascular diseases, systemic lupus erythematosus, leukemia, pulmonary tuberculosis, and cancer especially. Recently, mounting evidence has supported that circRNAs play a key role in the tumorigenesis, progress, invasion and metastasis in lung cancer. Its special structure-3'-5' covalent loop-allow it to execute several special functions in both normal eukaryotic cells and cancer cells. Our review summaries the latest studies on characteristics and biogenesis of circRNAs, and highlight the regulatory functions about miRNA sponge of lung-cancer-related circRNAs. In addition, the interaction of the circRNA-miRNA-mRNA regulatory network will also be elaborated in detail in this review. Therefore, this review can provide a new idea or strategy for further development and application in clinical setting in terms of early-diagnosis and better treatment.Entities:
Keywords: Circular RNAs; Lung neoplasms; ceRNA-miRNA-mRNA; miRNA sponge
Year: 2020 PMID: 32467668 PMCID: PMC7236303 DOI: 10.1186/s12935-020-01245-4
Source DB: PubMed Journal: Cancer Cell Int ISSN: 1475-2867 Impact factor: 5.722
Functions of circRNAs
| Function | Example | References |
|---|---|---|
| miRNA sponge | circ-HIPK3 circ-PRKCI | [ |
| Translation regulator | circ-PABPN1 | [ |
| Alternative splicing | circ-Mbl | [ |
| RNAP II elongation | circ-EIF3J circ-PAIP2 | [ |
| RNA maturation | circ-ANRIL | [ |
| Protein translation (including m6A-driven) | circ-ZNF609 | [ |
| Protein sponge | circ-Foxo3 | [ |
| Histone methylation | Circ-ANRIL | [ |
The summary of validated circRNA-miRNA-mRNA regulatory axes in lung cancer
| Cancer types | Sample | circRNA-miRNA-mRNA | Cell characteristics | Clinical characteristics | Clinical application | References |
|---|---|---|---|---|---|---|
| LAC | Tissues Plasma Cells | 1. Cell proliferation 2. Cell invasion 3. Cell apoptosis 4. Cell migration | 1. TNM stage 2. Lymph node metastasis | Diagnostic values AUC: 0.815 Sensitivity: 0.755 Specificity: 0.796 | [ | |
| NSCLC | Cells | 1. Cell proliferation | – | – | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell invasion 3. Cell apoptosis 4. Cell migration | 1. T stage 2. Lymph node metastases 3. TNM stage 4. Poor differentiation | – | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell apoptosis | 1. TNM stage 2. Lymph node metastasis 3. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell invasion 3. Cell apoptosis 4. Cell migration | 1. TNM stage 2. Lymph node metastasis 3. Poor differentiation 4. Survival rate | – | [ | |
| LAC | Tissues Cells | 1. Cell proliferation | 1. Tumor size | – | [ | |
| LAC | Tissues Cells | 1. Cell proliferation 2. Cell apoptosis | 1. Poor differentiation 2. TNM stage 3. Lymph node metastasis | – | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion 4. Cell apoptosis | 1. Histological grade 2. N stage 3. TNM stage | – | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell invasion | – | – | [ | |
| LAC | Tissues Cells | 1. Cell proliferation 2. Cell apoptosis | 1. TNM stage 2. Tumor size 3. T stage 4. Survival rate | Prognostic value | [ | |
| LAC | Tissues | – | 1. T stage 2. Distant metastasis | Diagnostic values AUC: 0.815 | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion 4. Cell apoptosis | 1. TNM stage 2. Lymph node metastasis 3. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion 4. Cell apoptosis | 1. TNM stage 2. Lymph node metastasis 3. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell invasion | 1. Tumor size 2. Lymph node metastasis 3. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion 4. Cell apoptosis | 1. Poor differentiation 2. Lymph node metastasis 3. T stage and N stage 4. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cell | 1. Cell proliferation 2. Cell apoptosis | – | – | [ | |
| NSCLC | Cells Mice | 1. Cell proliferation 2. Cell migration | – | – | [ | |
| LAC | Tissues Cells Mice | 1. Cell proliferation 2. Cell migration 3. Cell invasion 4. Cell apoptosis | 4. TNM stage | – | [ | |
| NSCLC | Tissues cells | 1. Cell proliferation 2. Cell invasion | 1. TNM stage 2. Lymph node metastasis 3. Tumor size 4. Poor differentiation 5. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells Mice | 1. Cell proliferation 2. Cell invasion | 1. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Blood Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion 4. Cell apoptosis | 1. Distant metastasis | Diagnostic values Tissues: AUC: 0.803 Sensitivity: 0.825 Specificity: 0.675 Serum: AUC: 0.794 Sensitivity: 0.711 Specificity: 0.800 | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell apoptosis | 1. Tumor size 2. TNM stage 3. Survival rate | Prognostic value | [ | |
| LAC | Tissues Cells | 1. Cell proliferation 2. Cell apoptosis | 1. TNM stage 2. Tumor size 3. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell invasion 3. Cell apoptosis | 1. TNM stage 2. Lymph node metastasis | – | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell invasion 3. Cell apoptosis | – | Diagnostic values AUC: 0.643 Sensitivity: 0.725 Specificity: 0.575 | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion | 1. TNM stage 2. Distant metastasis 3. Poor differentiation | – | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion 4. Cell apoptosis | 1. Lymph node metastasis 2. Poor differentiation 3. Survival rate | – | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion 4. Cell apoptosis | 1. TNM stage 2. Lymph node metastasis 3. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell invasion 3. Cell apoptosis | 1. TNM stage 2. T stage 3. Poor differentiation 4. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells | 1. Cell migration 2. Cell invasion | 1. Lymph node metastasis 2. Prognostic value | Prognostic value | [ | |
| NSCLC | TISSUES Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion 4. Cell apoptosis | – | – | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion 4. Cell apoptosis | 1. TNM stage 2. Lymph node metastasis | Prognostic value | [ | |
| SCLC | Tissues Blood | 1. Cell proliferation 2. Cell migration 3. Cell apoptosis | 1. Lymph node metastasis 2. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation | 1. Patients’ age (particularly after the age of 60) 2. TNM stage | – | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell invasion 3. Cell apoptosis | 1. TNM stage 2. Lymph node metastasis 3. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells | 1. Cell invasion 2. Cell metastasis | – | – | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion | 1. TNM stage 2. Lymph node metastasis 3. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion | 1. TNM stage 2. Lymph node metastasis 3. Survival rate | Prognostic value | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 3. Cell apoptosis | – | – | [ | |
| NSCLC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion | – | Diagnostic values AUC: 0.782 Sensitivity: 0.800 Specificity: 0.733 | [ | |
| LAC | Tissues Cells | 1. Cell migration 2. Cell invasion | 1. TNM stage 2. Lymph node metastasis | – | [ | |
| LAC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion | 1. TNM stage 2. Lymph node metastasis 3. Tumor size 4. Survival rate | Prognostic value | [ | |
| LAC | Tissues Cells | 1. Cell proliferation 2. Cell migration 3. Cell invasion | 1. T stage 2. Cell proliferation 3. Cell migration and invasion | – | [ |
Fig. 1The summary of clinical functions in lung cancer. All the circRNAs were concluded from validated circRNAs with circRNA-miRNA-mRNA regulatory network. CircRNAs included in our study were divided into 7 parts according to their clinical characteristics. As we can see in the picture, most of the circRNAs are significantly related to lymphatic metastasis and TNM stage
Fig. 2Summary of clinical characteristics of circRNAs in lung cancer. Percent in X axis means the studies involved in each clinical event take up in the whole studies about circRNA-miRNA-mRNA regulatory axis in lung cancer. Significance in each group means there is a significant relationship between clinical characteristics and certain circRNA. No significance in each group means no significance can be found between clinical characteristics and certain circRNA
Fig. 3The whole view of the biogenesis and function of circRNAs. The biogenesis of three kinds of circRNA (EIciRNA, ecircRNA and ciRNA) and eight kinds of function, including circRNA-miRNA-mRNA axis, were presented in the picture. a RNAP II elongation. b Histone methylation. c Alternative splicing. d RNA maturation. e miRNA sponge. f Translation splicing. g Protein sponge. h Protein translation (including m6A-driven)